Citigroup Maintains Buy on Candel Therapeutics, Lowers Price Target to $22
Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $24 to $22.
Login to comment